; and (ii) the Secretary determines within 6 months of the date of enactment of the Over-the-Counter Drug Safety, Innovation, and Reform Act , that it is in the interest of public health to extend the period during which the drug may be marketed without an approved new drug application under section 505. (D) A drug that is subject to the final monograph for sunscreen drug products set forth at part 352 of title 21, Code of Federal Regulations (as published at volume 64 page 27687 of the Federal Register), shall comply with the requirements of that monograph, except that the testing requirements for effectiveness and the provisions governing labeling shall be in accordance with section 201.327 of title 21, Code of Federal Regulations (as in effect on the date of enactment of the Over-the-Counter Drug Safety, Innovation, and Reform Act ), or such changes to those requirements as may be made under subsections (c), (d), and (j). (2) New drugs A nonprescription drug is a new drug within the meaning of section 201(p) and subject to the requirements of section 505 if the drug is— (A) not described in subparagraph (A), (B), or (D) of paragraph (1) and not in conformity with subsection (d); (B) not subject to an administrative final order pursuant to subsection (c); or (C) not a nonprescription sunscreen active ingredient or combination of ingredients subject to a final sunscreen order, as defined in section 586(2). (3) Monograph drug A nonprescription drug that is in compliance with paragraph (1) shall be referred to in this section as a monograph drug . (4) Rules of construction (A) In general This section shall not affect the treatment or status of a nonprescription drug subject to section 505— (i) that, on the date of enactment of the Over-the-Counter Drug Safety, Innovation, and Reform Act , is marketed without an application approved under section 505